PIMA512077

c-Myc Monoclonal Antibody (9E10.3), Biotin, Invitrogen™

Manufacturer: Thermo Scientific

Select a Size

Pack Size SKU Availability Price
Each of 1 PIMA512077-Each-of-1 In Stock ₹ 49,751.00

PIMA512077 - Each of 1

₹ 49,751.00

In Stock

Quantity

1

Base Price: ₹ 49,751.00

GST (18%): ₹ 8,955.18

Total Price: ₹ 58,706.18

Antigen

c-Myc

Classification

Monoclonal

Concentration

0.2 mg/mL

Formulation

PBS with 0.2% BSA and 0.09% sodium azide; pH 7.4

Gene Accession No.

P01106

Gene Symbols

MYC

Immunogen

A synthetic peptide, aa 408-439, (AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA) from C-terminus of human c-myc

Quantity

500 μL

Primary or Secondary

Primary

Target Species

Human

Product Type

Antibody

Isotype

IgG1 κ

Applications

Flow Cytometry, Immunohistochemistry (Paraffin), Immunomicroscopy, Immunoprecipitation, Western Blot

Clone

9E10.3

Conjugate

Biotin

Gene

MYC

Gene Alias

AU016757; Avian myelocytomatosis viral (v-myc) oncogene homolog; avian myelocytomatosis viral oncogene homolog; bHLHe39; c Myc; class E basic helix-loop-helix protein 39; cmyc; c-Myc; c-myc epitope tag; c-myc proto-oncogene; mMyc; MRTL; Myc; Myc protein; Myc proto-oncogene protein; MYC proto-oncogene, bHLH transcription factor; Myc2; MYCC; myc-related translation/localization regulatory factor; myelocytomatosis oncogene; myelocytomatosis viral oncogene homolog; Niard; Nird; Proto-oncogene c-Myc; RNCMYC; Transcription factor p64; v-myc avian myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene homolog; v-myc myelocytomatosis viral oncogene-like protein

Host Species

Mouse

Purification Method

Protein G

Regulatory Status

RUO

Gene ID (Entrez)

4609

Content And Storage

4° C

Form

Liquid

Related Products

Img

Novus Biologicals

NB200108W

--

Img

Novus Biologicals

NB338693

--

Img

Novus Biologicals

NB371643

--

Img

Novus Biologicals

NB454469

--

Img

Novus Biologicals

NBP234691UV

--

Img

Novus Biologicals

NBP234691R

--

Img

Novus Biologicals

NB289123

--

Img

Novus Biologicals

NB271059PCP

--

Description

  • MA5-12077 targets c-myc in FACS, IF, IHC (P), IM, IP, and WB applications and shows reactivity with Human samples
  • The MA5-12077 immunogen is a synthetic peptide, aa 408-439, (AEEQKLISEEDLLRKRREQLKHKLEQLRNSCA) from C-terminus of human c-myc
  • The c-Myc protein is a 62 kDa transcription factor that is encoded by the c-Myc gene on human chromosome 8q24
  • c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression
  • The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation
  • Studies have shown that c-Myc is essential for vasculogenesis and angiogenesis in tumor development, which distributes blood throughout the cells
  • The c-myc oncogene (p62 c-myc) is involved in the control of normal cellular proliferation and differentiation, and the deregulated expression of c-Myc induces apoptosis in different cell types
  • Antibodies against c-myc epitopes recognize overexpressed proteins containing Myc epitope tag fused to either amino- or carboxy-termini of targeted proteins
  • c-Myc-, N-Myc- and L-Myc-encoded proteins function in cell proliferation, differentiation and neoplastic disease
  • Amplification of the c-Myc gene has been found in several types of human tumors including lung, breast and colon carcinomas, while the N-Myc gene has been found amplified in neuroblastomas
  • Translocation of the c-myc locus on chromosome 8 to the immunoglobulin loci on chromosome 14 (heavy chain); 2 (delta light chain); or 22 (light chain) is described in Burkitts lymphoma and other B-cell lymphoproliferative conditions
  • An aberrant expression of the c-myc gene occurs in tumors of different origins such as colorectal, gastric, gallbladder, hepatic, mammary, ovarian, endometrial, head and neck, pulmonary, prostatic, thyroidal, oral, ocular, nasopharyngeal, endocrine, as well as hematopoietic neoplasms.